The phase 2, randomized placebo-controlled trial will evaluate safety and efficacy of autologous stromal and vascular fraction cells that are injected after rotator cuff repair. Fifty-six patients are expected to be enrolled.
The Tissue Genesis Icellator was acquired by Orgenesis in 2020. It’s an investigational device in the U.S. and is a system for recovering autologous stromal and vascular fraction cells from fat tissue.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
